EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities

Daniele Focosi

Current Topics in Microbiology and Immunology · 2024

DOI: 10.1007/82_2024_268 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Topics in Microbiology and Immunology, 2024. Verfasst von Daniele Focosi. Beteiligte Einrichtung: North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy. daniele.focosi@gmail.com. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Monoclonal, COVID-19 Drug Treatment, Antibodies, Viral. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 117 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antibodies, MonoclonalCOVID-19 Drug TreatmentAntibodies, ViralHumansCOVID-19Spike Glycoprotein, CoronavirusAnimalsAntibodies, Neutralizing

Stichwörter der Autor:innen

AdintrevimabBamlanivimabBebtelovimabCOVID-19CasirivimabCilgavimabEtesevimabImdevimabMonoclonal antibodiesREGEN-COVREGN-CoV-2RegdanvimabSotrovimabSpikeTixagevimab

Substanzen

Antibodies, MonoclonalSpike Glycoprotein, CoronavirusAntibodies, Viralspike protein, SARS-CoV-2Antibodies, Neutralizing

Autor:innen und Institutionen

  • North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy. daniele.focosi@gmail.com.

Zitieren

APA

Focosi, D. (2024). Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities. Current Topics in Microbiology and Immunology. https://doi.org/10.1007/82_2024_268

Vancouver

Focosi D. Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities. Current Topics in Microbiology and Immunology. 2024. doi:10.1007/82_2024_268

BibTeX
@article{Focosi2024,
  author = {Focosi, Daniele},
  title = {Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities},
  journal = {Current Topics in Microbiology and Immunology},
  year = {2024},
  doi = {10.1007/82_2024_268}
}
Kostenlos starten →